181- Fumery M, Jacob A, Sarter H, et al. Efficacy and safety of adalimumab after infliximab failure
in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015;60:744–8. - Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalim-
umab therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol. 2009;104:3042–9. - Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric
Crohn’s disease. Am J Gastroenterol. 2009;104:2566–71. - Hyams JS, Griffiths A, Markowitz J, et al. Safety and efficacy of adalimumab for moderate to
severe Crohn’s disease in children. Gastroenterology. 2012;143:365–74.e2. - Dubinsky MC, Rosh J, Faubion WA Jr, et al. Efficacy and safety of escalation of adalim-
umab therapy to weekly dosing in pediatric patients with Crohn’s disease. Inflamm Bowel Dis.
2016;22:886–93. - Faubion WA, Dubinsky M, Ruemmele FM, et al. Long-term efficacy and safety of adalimumab
in pediatric patients with Crohn’s disease. Inflamm Bowel Dis. 2017;23:453–60. - Volonaki E, Mutalib M, Kiparissi F, Shah N, Lindley KJ, Elawad M. Adalimumab as a second-
line biological therapy in children with refractory ulcerative colitis. Eur J Gastroenterol
Hepatol. 2015;27:1425–8. - Park KT, Sin A, Wu M, Bass D, Bhattacharya J. Utilization trends of anti-TNF agents and
health outcomes in adults and children with inflammatory bowel diseases: a single-center
experience. Inflamm Bowel Dis. 2014;20:1242–9. - Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory
bowel disease. J Pediatr Gastroenterol Nutr. 1993;16:373–80. - Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with
inflammatory bowel disease: a prospective study. Gastroenterology. 1993;105:681–91. - Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for
the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel
Dis. 2008;14:839–49. - Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a
decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model
of colitis. Gut. 2000;46:694–700. - Kleinman RE, Baldassano RN, Caplan A, et al. Nutrition support for pediatric patients with
inflammatory bowel disease: a clinical report of the North American Society for Pediatric
Gastroenterology, Hepatology And Nutrition. J Pediatr Gastroenterol Nutr. 2004;39:15–27. - Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cyto-
kines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr.
2006;43:144–55. - Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in
children with chronically active severe Crohn’s disease. Inflamm Bowel Dis. 2007;13:424–30. - Malik S, Ahmed SF, Wilson ML, et al. The effects of anti-TNF-alpha treatment with adalim-
umab on growth in children with Crohn’s disease (CD). J Crohns Colitis. 2012;6:337–44. - Cameron FL, Altowati MA, Rogers P, et al. Disease status and pubertal stage predict improved
growth in antitumor necrosis factor therapy for pediatric inflammatory bowel disease. J Pediatr
Gastroenterol Nutr. 2017;64:47–55. - Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease
following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid
reduction. J Pediatr Gastroenterol Nutr. 2011;52:31–7. - DeBoer MD, Thayu M, Griffin LM, et al. Increases in sex hormones during anti-tumor necro-
sis factor alpha therapy in adolescents with Crohn’s disease. J Pediatr. 2016;171:146–52.e1-2. - Vespasiani Gentilucci U, Caviglia R, Picardi A, et al. Infliximab reverses growth hor-
mone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther.
2005;21:1063–71. - Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral
density in children with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:42–50.
11 Biologic Therapy in Pediatric Inflammatory Bowel Disease